The EG95 protein has occupied a special place in echinococcosis research since its discovery as a protective antigen from oncosphere-stage parasites. Recombinant EG95-based vaccines have shown efficacy in sheep and have been deployed in some control programs, but the platform has persistent weaknesses. Protein subunit vaccines tend to elicit immune responses that wane relatively quickly, requiring booster doses and careful scheduling to maintain protection in flocks. Their production depends on expression systems that can be technically demanding, and the immunogenicity of the purified antigen, while real, is modest compared with what newer vaccine technologies can achieve. For a neglected zoonotic disease whose control depends on vaccinating large numbers of livestock in resource-limited settings, those limitations matter enormously.

The Chinese research group, whose members span institutions working on parasitic diseases and veterinary science, reasoned that the mRNA-lipid nanoparticle platform, which transformed human vaccinology during the COVID-19 pandemic, could address these shortcomings. mRNA vaccines instruct the recipient’s own cells to manufacture the target antigen, which means the protein is produced in its native form, with appropriate folding and post-translational modifications, and presented to the immune system in a context that engages both antibody and T-cell arms of immunity. The lipid nanoparticles that deliver the messenger RNA also act as built-in adjuvants, stimulating innate immune sensors that amplify the adaptive response. Manufacturing is fast, scalable, and does not require cell culture systems specific to each antigen, making the platform attractive for diseases that have never attracted the commercial investment of human medicine.

From this starting point, the team designed three vaccine candidates. The first was a straightforward EG95 mRNA-LNP vaccine, encoding the canonical protective antigen. The second, an IL-4-EG95 mRNA-LNP vaccine, was more inventive: it encoded a fusion protein in which EG95 was joined to interleukin-4, an immune signaling molecule, via a flexible peptide linker. The idea was to exploit the cytokine as a molecular adjuvant, tethering an immunostimulatory signal directly to the antigen so that cells taking up the vaccine would present EG95 in a context primed to enhance immune activation. The third candidate, an EG95-EC95 mRNA-LNP vaccine, took a multivalent approach, incorporating EC95 antigens derived from Echinococcus canadensis, a related parasite species within the E. granulosus sensu lato complex. Because the parasite species complex encompasses organisms with antigenic variation, a formulation that covers multiple variants could broaden protection across the range of parasites circulating in different regions and host species.

The researchers confirmed that all three vaccine candidates were efficiently encapsulated in lipid nanoparticles and that the encoded antigens were robustly expressed both in cell culture and in vaccinated animals. Expression of the target protein is the essential first step for any mRNA vaccine, and the fusion constructs, despite their added complexity, performed well. With the platform validated in vitro, the team moved to animal studies, comparing the mRNA vaccines head-to-head with a commercial EG95 subunit vaccine, the benchmark against which any new echinococcosis vaccine must be measured.

The immunological results were striking. In both mice and lambs, the mRNA-LNP vaccines induced humoral and cellular immune responses that were significantly stronger than those provoked by the subunit vaccine. Antibody titers rose higher and, critically, persisted longer: the animals maintained high levels of EG95-specific antibodies for more than twelve months after vaccination. For a livestock vaccine intended to protect animals through the period when they are most vulnerable to infection and through the breeding cycles of a working flock, that durability is a decisive advantage. It suggests that a vaccination schedule built on the mRNA platform could achieve with fewer doses what currently requires repeated boosters, reducing the logistical burden on herders and veterinary services in endemic regions.

Cellular immunity, often the neglected dimension in evaluations of antiparasitic vaccines, also differed markedly between the platforms. The mRNA vaccines engaged T-cell responses to a degree the subunit formulation did not match, a consequence of the way lipid nanoparticles deliver their cargo into cells and stimulate innate immune pathways. Because the immune response to Echinococcus involves both antibodies that attack oncospheres as they attempt to establish infection and cellular mechanisms that shape the environment around developing parasites, the breadth of the response induced by the mRNA platform may explain much of its protective superiority.

The decisive test came from parasite challenge experiments. When vaccinated animals were exposed to Echinococcus infection, the three mRNA-LNP vaccines all conferred protection, but the IL-4-EG95 fusion vaccine stood out. In animals receiving that formulation, the survival of protoscoleces, the larval forms that seed hydatid cysts, was inhibited, and the growth of cysts that did establish was suppressed. The fusion of the cytokine to the antigen, an approach that might have backfired by skewing immunity in an unhelpful direction, instead delivered the most effective protection of any candidate tested. The result validates the concept of genetically adjuvanted mRNA vaccines for parasitic diseases and suggests that the IL-4-EG95 construct is the leading candidate for further development.

The implications extend beyond echinococcosis itself. Cystic echinococcosis is one of many neglected zoonotic diseases for which the economics of vaccine development have never worked in favor of conventional platforms. The mRNA approach offers safety, scalability, and flexibility: the same lipid nanoparticle technology can be adapted to new antigens simply by changing the encoded sequence, and manufacturing does not depend on the biological quirks of expression systems. For a disease whose control requires coordinated vaccination of livestock, deworming of dogs, and public health surveillance across vast rural landscapes, a vaccine that is both more effective and longer-lasting could shift the calculus of elimination programs that have struggled for decades.

The study, published in PLOS Pathogens, positions EG95-based mRNA vaccines as a promising strategy for reducing the transmission of E. granulosus sensu lato and, with it, the zoonotic burden of cystic echinococcosis in the communities where the parasite remains endemic. Challenges remain before the platform reaches the field, including the regulatory pathways for veterinary mRNA vaccines, cold-chain requirements for lipid nanoparticle formulations, and the scale-up of challenge studies in livestock under natural transmission conditions. But the demonstration that mRNA vaccines can outperform the established subunit benchmark in both magnitude and duration of immunity, and that a cytokine-antigen fusion can push protection even further, gives researchers and control programs a concrete new tool to pursue. For a neglected disease that has waited decades for a technological leap, the arrival of one may finally be at hand.

Subject of Research: Development of EG95-based mRNA-lipid nanoparticle vaccines inducing long-term protective immunity against cystic echinococcosis

Article Title: Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis

Article References: Novel EG95-based mRNA vaccines induce long-term protective immunity against echinococcosis. (n.d.). https://doi.org/10.1371/journal.ppat.1014659

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014659

Keywords: echinococcosis, Echinococcus granulosus, EG95, mRNA vaccine, lipid nanoparticles, zoonotic disease, veterinary vaccinology, humoral immunity, IL-4, parasitology, vaccine development, one health